Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96S42

UPID:
NODAL_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q96S42; Q2M3A5; Q8N4V3

BACKGROUND:
Nodal homolog, a key protein in embryogenesis, is essential for the proper formation of the mesoderm and for the axial patterning that determines the left-right asymmetry of thoracoabdominal organs. This protein's function is critical in directing the developmental fate of cells and tissues in the embryo.

THERAPEUTIC SIGNIFICANCE:
Alterations in the Nodal homolog protein are implicated in the development of Heterotaxy, visceral, 5, autosomal, a condition marked by the disarrayed placement of internal organs and complex cardiac anomalies. Targeting the pathways involving Nodal homolog offers a promising avenue for the development of novel interventions for heterotaxy and related congenital abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.